Exact Sciences clears FDA panel; Roche wins EU nod for subcutaneous Rituxan;

@FierceBiotech: Our 1st EuroBiotech Report: Merck KGaA R&D chief exits, Sobi drug flops in PhIII, Adaptimmune gets full-time CEO. Report | Follow @FierceBiotech

@JohnCFierce: Novartis is using Twitter to support its R&D team at adcomms? Social media won't substitute for another serelaxin trial. More | Follow @JohnCFierce

@DamianFierce: Syndax swings for a $69M IPO with 'breakthrough' drug in tow. News | Follow @DamianFierce

@EmilyMFierce: Report: U.S. can do more to support global health R&D. Article via FierceBiotech Research | Follow @EmilyMFierce

> Exact Sciences ($EXAS) won an FDA panel's unanimous recommendation for its stool-based colorectal cancer diagnostic. News

> Roche ($RHHBY) won European approval for a subcutaneous version of the cancer drug Rituxan. Story

Medical Device News

@FierceMedDev: An analyst thinks Smith & Nephew should split into three pieces, and investors loved the idea. Story | Follow @FierceMedDev

@MarkHFierce: Check out FierceBiotech's debut EuroBiotech report. Report | Follow @MarkHFierce

@MichaelGFierce: Small, drug-releasing battery could dissolve completely over time. Article via FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: GN Store Nord's U.S. customer base gets a boost thanks to its bluetooth-like hearing aid. Article | Follow @EmilyWFierce

> In Ohio, Steris slashes jobs and plans to close a plant. More

> Exact Sciences wins unanimous FDA committee approval for its colon cancer Dx. News

> NeuroSigma brings on two Amgen execs to bolster its finance team. Item

Pharma News

@FiercePharma: Top-read FP story yesterday: Merck, GlaxoSmithKline halt copay help for Obamacare patients. Story | Follow @FiercePharma

@TracyStaton: RT: Just out: today's full issue of FiercePharmaMarketing. More | Follow @TracyStaton

@EricPFierce: FDA's Woodcock throws cold water on research that found foreign-made generics of Lipitor tainted. Article | Follow @EricPFierce

@CarlyHFierce: Check out FierceBiotech's new EuroBiotech report, which will run every Friday from here on out. Report | Follow @CarlyHFierce

> Roche nabs European approval for time-saving formulation of Rituxan. More

> Hospira puts shareholder lawsuit behind it with $60M settlement. News

> Regeneron clears roadblock for new plant in Irish tax haven. Story

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.